About our Instructors:
Dennis L. Cooper, M.D.
Professor of Medicine (Hematology)
Yale Cancer Center
Dennis Cooper, MD, is a Professor of Internal Medicine(Hematology) at the Yale School of Medicine. Following graduation from RushMedical School, he completed his residency in Internal Medicine at Yale-NewHaven Hospital followed by a chief residency at the University of Pittsburgh. He returned to Yale for his fellowship training and then served as Fellowship Director and Clinical Director of the Hematopoietic Stem Cell Transplant Service. His clinical interests are recurrent lymphoma, multiple myeloma, and hematopoietic stem cell transplantation.Carol Ann Huff, M.D.Associate Professor of Medicine and Oncology,Director, Myeloma Program, Division of Hematologic MalignanciesSidney Kimmel Comprehensive Cancer Center
Carol Ann Huff, MD, is an Assistant Professor of Oncology and Medicine at the Johns Hopkins University School of Medicine in Baltimore, Maryland, where she is also the Director of the Myeloma Program in the Division of Hematologic Malignancies.
Dr. Huff's research interest is in developing novel biologically-based therapies for myeloma including attempts to target myeloma stem cells and immune-based approaches. Her efforts have focused on improving response rates and overall survival for patients with multiple myeloma as well as reducing the toxicity of bone marrow transplantation coupled with efforts to develop a targeted immune attack post-transplantation.
Prior to receiving her medical degree from Baylor College of Medicine, Dr. Huff completed a Bachelor of Science in Zoology at Duke University in Durham, NC. She completed her internship and residency at the Johns Hopkins University School of Medicine before joining the Department of Medicine as an Instructor where she was later promoted to Assistant Professor. Dr. Huff went on to complete a clinical fellowship in Oncology before formally accepting a joint appointment in the Oncology department.
Dr. Huff has authored many peer-reviewed articles, book chapters, and monographs in the field of myeloma research and is a leading national speaker on this topic.
Mark Levis, M.D.Associate Professor of Oncology, Pharmacology, and MedicineSidney Kimmel Comprehensive Cancer CenterMark Levis, M.D., Ph.D. has been Member of the Hematology and Oncology Clinical Advisory Board of Ambit Biosciences Corporation since February 28, 2008. Dr. Levis serves as Assistant Professor at Johns Hopkins University in Baltimore. Mr. Levis laboratory research focuses on the development of molecularly targeted therapies for leukemia. Currently, he is actively involved in the pre-clinical and clinical development of small molecule inhibitors of the receptor tyrosine kinase, FLT3. He served as Member of Scientific Advisory Board at Symphogen A/S.
Levis, M., Tse, K-F., Smith, B.D., Garrett, E., and Small, D. (2001). A FLT3 tyrosine kinase inhibitor is cytotoxic to AML blasts harboring a FLT3/ITD mutation. Blood. 98:885.
Levis, M., Allebach, J., Tse, K-F., Sheng, R., Baldwin, B.R., Smith, B.D., Jones-Bolin, S., Ruggeri, B., Dionne, C., and Small, D. (2002). A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 99:3885.
Smith, B.D., Levis, M., Beran, M., Giles, F., Brown, P., Russell, L., Hellriegel, E., Murphy, K., Dauses, T., Allebach, J., and Small, D. (2004) Single agent CEP-701, a novel FLT3 inhibitor, shows initial response in patients with refractory acute myeloid leukemia. Blood. 103:3669
Levis, M. and Small, D. (2003). FLT3:ITDoes matter in leukemia. Leukemia. 17:1738.
Murphy, K.M., Levis, M., Hafez, M.J., Geiger, T., Cooper, L.C., Smith, B.D., Small, D., and Berg, K.D. (2003). Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn. 5: 96-102.
Zheng, R., Levis, M, Piloto O, Brown P, Baldwin B., and Small, D. (2003) FLT3 ligand (FL) causes autocrine signaling in AML cells. Blood. 103:267.
Levis, M., and Small, D. (2004). Small molecule FLT3 tyrosine kinase inhibitors. Current Pharmaceutical Design. 10:1183.
B. Douglas Smith, M.D.Associate Professor, Hematologic MalignanciesSidney Kimmel Comprehensive Cancer Center
Dr. Smith graduated from Drexel University College of Medicine in 1991. Dr. Smith’s expertise includes acute lymphoblastic leukemia, acute myeloid leukemia, blood transplant, bone marrow transplant, chronic myeloid leukemia , drug development, hematologic malignancies, leukemia, medical oncology, myelodysplasia, myelodysplastic syndrome, myeloproliferative disorders. His research interests include acute and chronic leukemias; myeloid disorders and bone marrow transplantation.
B. Douglas Smith, MD, received his medical degree from the Medical College of Pennsylvania in Philadelphia, Pennsylvania, followed by internship, residency, and a Chief Residency in Internal Medicine at the University of Rochester’s Strong Memorial Hospital. Dr. Smith went on to complete his Oncology Fellowship at The Johns Hopkins University School of Medicine in Baltimore, Maryland. Dr. Smith joined the faculty at Johns Hopkins upon completion of his training and is now an Associate Professor of Oncology.
Dr. Smith’s research focuses on taking new and promising laboratory insights and developing them into biology based treatment approaches for patients with myeloid malignancies. He has developed close laboratory collaborations and has focused on the clinical development of three main areas: cancer stem cell biology and differentiation-based treatment approaches, signal transduction and targeted drug development, and immunotherapy using vaccine strategies.
Clinically, Dr. Smith’s interests center on treating patients with myeloid malignancies, including acute and chronic myeloid leukemias, and myelodysplastic syndromes. He is recognized as a national leader in these areas and serves on the NCCN Guideline Panel for both AML and CML. Dr. Smith also supports the SKCCC at Johns Hopkins through his participation on the Johns Hopkins Institutional Review Board.
250 First Avenue, Suite 300
Needham, MA 02494
Biological Therapeutic Products
Biomarkers & Diagnostics
Bioprocess & Manufacturing
Clinical Trials & Translational Medicine
Drug & Device Safety
Drug Discovery & Development
IT & Informatics
Technology & Tools For Life Science
Cambridge Healthtech Institute
Cambridge Innovation Institute